Personalized Physiology Analytics Engine software
VGBio, Inc (DBA PhysIQ) • Cardiovascular • 06/11/2015
Device Purpose
The Personalized Physiology Analytics Engine is a software tool that establishes an individual's unique physiological baseline by analyzing heart rate, respiration rate, and activity data collected during daily life. It then calculates a Multivariate Change Index (MCI) to indicate how current interrelationships among these vital signs deviate from this established baseline, offering clinicians supplementary, retrospective information for patient assessment.
Summary
The Personalized Physiology Analytics Engine (PPA Engine) is a computerized analysis software program designed to detect changes in the relationships among an ambulatory patient's vital signs, using data from already cleared multi-parameter physiological sensors. It processes inputs of Heart Rate (HR), Respiration Rate (RR), and Activity (ACT). The core methodology involves the PPA Engine first 'learning' a patient-specific baseline, defined by the typical interrelationships among these vital signs as measured during the patient's routine activities of daily living. Once this personalized baseline is established, the software analyzes subsequent incoming data to assess how the current relationships among these vital signs compare to this learned baseline, providing a continuous assessment reflecting the patient's activities. The primary output of the PPA Engine is the Multivariate Change Index (MCI), a scalar value ranging from 0 to 1. An MCI value closer to 0 indicates that the monitored relationships among the vital signs are similar to the patient's learned baseline, whereas a value closer to 1 suggests that these relationships are likely different. The MCI is presented as a time series intended for daily, intermittent, retrospective review by a qualified practitioner. It serves as an adjunct to, and is not intended to replace, standard vital signs monitoring or be used for direct clinical decision-making or diagnostic purposes. Bench testing verified the device meets its specifications, and clinical testing on healthy volunteers, including a study involving altitude changes, demonstrated that the MCI effectively correlates with changes in the monitored relationships among vital signs compared to the subject's established baseline.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How sensitive is the Multivariate Change Index (MCI) to subtle physiological changes, and what is the typical timeframe required to establish a reliable personalized baseline for different patient populations?; What specific algorithms or computational methods are used to 'learn' the patient's personalized baseline and then calculate the MCI from heart rate, respiration rate, and activity data?; In the clinical validation studies, what was the magnitude of altitude change, and were specific thresholds for MCI established that correlated with clinically observable physiological stress or adaptation in the healthy volunteers?; How does the PPA Engine account for normal diurnal variations or expected physiological responses to non-pathological stimuli (e.g., moderate exercise, emotional stress, sleep stages) when establishing the baseline and calculating subsequent MCI values?; What are the potential applications or benefits of using a retrospective MCI in managing ambulatory patients, and are there specific clinical scenarios where this supplementary information has been shown to be particularly insightful?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class C (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, HBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Not detected in AI-generated device summary: SBOM, SaaSBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly